Cargando…

Abacavir forms novel cross-linking abacavir protein adducts in patients

Detalles Bibliográficos
Autores principales:	Meng, Xiaoli, Lawrenson, Alexandre, Berry, Neil, Maggs, James, French, Neil, Back, David, Khoo, Saye, Naisbitt, Dean, Park, Kevin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127564/ http://dx.doi.org/10.1186/2045-7022-4-S3-P38

Ejemplares similares

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Platelet activity in HIV-infected patients on abacavir-containing antiretroviral therapy
por: Palacios, R, et al.
Publicado: (2010)

Evaluation of a pharmacogenetic test in Thailand for abacavir hypersensitivity screening in human immunodeficiency virus infection
por: Chonlaphat, Sukasem, et al.
Publicado: (2014)

Role of platelet activation in the cardiovascular complications associated with HIV infection: differential effect of abacavir versus tenofovir
por: Francisci, D, et al.
Publicado: (2010)

Abacavir-induced liver toxicity
por: Pezzani, Maria Diletta, et al.
Publicado: (2016)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

Abacavir methanol 2.5-solvate
por: Pham, Phuong-Truc T.
Publicado: (2009)

Alopecia Areata Associated with Abacavir Therapy
por: Kim, Hee-Sung, et al.
Publicado: (2014)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Pharmacokinetics of lamivudine, abacavir and zidovudine administered twice daily as syrups versus scored tablets in HIV-1-infected Ugandan children
por: Gitta, PK, et al.
Publicado: (2010)

Response to treatment of hepatitis C in HCV/HIV co-infected patients is not influenced by either abacavir or tenofovir with weight-based ribavirin
por: Bhatti, L, et al.
Publicado: (2010)

Relaxation Effect of Abacavir on Rat Basilar Arteries
por: Li, Rachel Wai Sum, et al.
Publicado: (2015)

Structural Elements Recognized by Abacavir-Induced T Cells
por: Yerly, Daniel, et al.
Publicado: (2017)

Abacavir use is associated with increased prothrombin conversion
por: Yan, Qiuting, et al.
Publicado: (2023)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
por: Evgenidou, Eleni, et al.
Publicado: (2023)

Isoniazid-specific T-cell Responses in patients with anti-tuberculosis drug related liver injury
por: Usui, Toru, et al.
Publicado: (2014)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010)

ProTide generated long-acting abacavir nanoformulations
por: Lin, Zhiyi, et al.
Publicado: (2018)

The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome
por: Fodor, James, et al.
Publicado: (2019)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Antigen exposure required for T cell activation
por: Meng, Xiaoli, et al.
Publicado: (2014)

Stress Degradation Behavior of Abacavir Sulfate and Development of a Suitable Stability-Indicating UHPLC Method for the Determination of Abacavir, its Related Substances, and Degradation Products
por: Vukkum, Pallavi, et al.
Publicado: (2012)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Abacavir-Reactive Memory T Cells Are Present in Drug Naïve Individuals
por: Lucas, Andrew, et al.
Publicado: (2015)

Regional Experience of Abacavir: Valuable but Still has Unanswered Question
por: Bang, Ji Hwan
Publicado: (2017)

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects
por: Gall, Eline, et al.
Publicado: (2022)

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing
por: Pražáková, Lucie, et al.
Publicado: (2023)

Safety and Efficacy of Ziagen (Abacavir Sulfate) in HIV-Infected Korean Patients
por: Ann, Heawon, et al.
Publicado: (2017)

Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir
por: Rabie, Helena, et al.
Publicado: (2020)

Abacavir antiretroviral therapy and indices of subclinical vascular disease in persons with HIV
por: Martinez, Claudia A., et al.
Publicado: (2022)

1028. Long-term Follow-up After a Switch to Bictegravir, Emtracitabine, Tenofovir Alafenamide from Dolutegravir, Abacavir, Lamivudine
por: Brar, Indira, et al.
Publicado: (2020)

Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV-infected women
por: MacLeod, Iain J, et al.
Publicado: (2012)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Factors in AIDS Dementia Complex Trial Design: Results and Lessons from the Abacavir Trial
por: Brew, Bruce J, et al.
Publicado: (2007)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
por: Rasmussen, Thomas A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_86871h77i29essuu5vnj75e33b